NEW YORK, July 17, 2017 /PRNewswire/ -- Xarelto lawsuits continue to mount in courts around the U.S., as do reports of life-threatening internal bleeding and other serious complications potentially related to its use. According to the Institute for Safe Medication Practices' (ISMP) latest issue of QuarterWatch, the U.S. Food & Drug Administration (FDA) received 21,996 adverse event reports involving blood-thinning medications during the calendar year ending 2016. Xarelto was implicated in more than 68% (15,043) of the cases.
"Our Firm is representing Xarelto lawsuit plaintiffs who were allegedly harmed by this drug. We are not surprised that adverse events related to this blood-thinner continue to climb," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm continues to evaluate potential Xarelto lawsuits on behalf of individuals who may have been harmed by this blood-thinning medication.
Xarelto was approved by the FDA in October 2011. Bayer and Johnson & Johnson have positioned the blood-thinner as an improvement over warfarin, an anticoagulant that has been in use for decades. However, the ISMP noted that warfarin was named in just 1,074 adverse event reports last year.
Serious internal bleeding can occur with any blood-thinner. However, there is currently no approved antidote to reverse hemorrhaging associated with Xarelto. Internal bleeding related to warfarin can be stopped via the administration of vitamin K.
More than 17,000 Xarelto lawsuits are currently pending in a multidistrict litigation underway in the U.S. District Court, Eastern District of Louisiana, where all federally-filed product liability claims involving the medication have been centralized for coordinated pretrial proceedings. Plaintiffs claim that Xarelto was wrongly promoted as an improvement to warfarin, citing the lack of an agent to reverse its anticoagulant effects. They also claim that Bayer and Johnson & Johnson failed to provide the public with adequate warnings regarding the true potential for Xarelto-related bleeding events. (In Re: Xarelto Products Liability Litigation, No. 2592)
Xarelto patients who allegedly experienced bleeding-related complications may be entitled to compensation for their medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP